AndzonBio2 Partners with Cambridge to Develop First-in-Class Neuroinflammation Therapeutics
核心洞察
AndzonBio2 (搜索) has signed agreements with the ALBORADA Drug Discovery Institute (搜索) at the University of Cambridge and Cambridge Enterprise (搜索) to develop novel therapeutics targeting neuroinflammation (搜索) in neurodegenerative diseases.
The collaboration aims to advance a first-in-class therapeutic program designed to modulate key pathways involved in neuroinflammatory processes affecting conditions like Parkinson's, Alzheimer's, and ALS.
Cambridge Enterprise (搜索) grants AndzonBio2 (搜索) an exclusive option to license resulting intellectual property and advance the program through preclinical and clinical development phases.
AndzonBio2 (搜索) announced the signing of agreements with the ALBORADA Drug Discovery Institute (搜索) (ADDI) at the University of Cambridge and Cambridge Enterprise (搜索) to advance a new class of therapeutics targeting neuroinflammation (搜索), a central driver of multiple neurodegenerative and neurological conditions including Parkinson's disease (搜索), Alzheimer's disease (搜索), Amyotrophic Lateral Sclerosis (搜索), and other central nervous system disorders.
The collaboration addresses a significant global health challenge, as neurological and neurodegenerative disorders affect over 3 billion people worldwide, with effective disease-modifying treatments remaining limited. Increasing scientific evidence highlights neuroinflammation (搜索) as a key biological driver of disease progression, making it an important emerging target for therapeutic innovation.
Strategic Partnership Framework
Under the agreement, the parties will combine AndzonBio2 (搜索)'s expertise in early drug development and translational strategy with Cambridge's world-leading neuroscience capabilities and ADDI's drug discovery platform. Together, they aim to progress a novel, first-in-class therapeutic program designed to modulate key pathways involved in neuroinflammatory processes.
The program is based on cutting-edge biology and represents an emerging area of significant scientific and commercial interest. Cambridge Enterprise (搜索) grants AndzonBio2 (搜索) an exclusive option to license the resulting intellectual property from the collaboration and advance the program through preclinical and clinical development.
Leadership Perspectives
"We are thrilled to enter this collaboration with the ADDI at Cambridge," said Loic Lhuillier, CEO of AndzonBio2 (搜索). "Neuroinflammation (搜索) is at the core of many severe brain diseases and new therapeutic solutions are urgently needed. By combining our complementary strengths, we have a unique opportunity to accelerate the development of a highly innovative therapeutic approach with the potential to change the treatment landscape for patients."
Professor John Skidmore, Chief Scientific Officer of the ALBORADA Drug Discovery Institute (搜索) at the University of Cambridge, emphasized the partnership's potential: "We are delighted to collaborate with AndzonBio2 (搜索) on this promising project. This partnership exemplifies our commitment to translating cutting-edge neuroscience into impactful therapies. AndzonBio2 brings a focused expertise in neuroinflammation (搜索) and drug development that will be instrumental in driving this promising programme forward."
Development Strategy
The partnership is structured to efficiently integrate academic discovery with industry-grade drug development, enabling rapid progress toward candidate nomination and future clinical testing. This approach aims to bridge the gap between deep disease understanding in academia and the drug development capabilities within the pharmaceutical and biotechnology industry.
The agreement reinforces Cambridge's and ADDI's mission to catalyze innovation in neuroscience through partnerships with organizations capable of translating discoveries into real-world therapeutic opportunities. AndzonBio2 (搜索)'s strategic focus on neuroinflammation (搜索) aligns with the growing recognition of this pathway's critical involvement in multiple brain disorders.